Pharmaron Beijing revenue and financials
In the fiscal year ended December 2025, Pharmaron Beijing reported revenue of ¥14.1B (+14.82% year over year). Net income was ¥1.66B, a net margin of 11.8%.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- +14.82%
- 2025 vs 2024
- Net income growth
- −7.22%
- 2025 vs 2024
- Net margin
- 11.8%
- 2024: 14.6%
How Pharmaron Beijing is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 22.4% a year on average over the last 5 years
Compound annual growth rate: from ¥5.13B in 2020 to ¥14.1B in 2025.
Revenue has grown for 9 fiscal years in a row
Each fiscal year compared with the one before, up to 2025.
Operating margin fell from 16.2% to 14.5%
Operating income over revenue, 2022 → 2025: 1.7 percentage points.
Less cash than profit: free cash flow equal to 19% of net income
Totals for fiscal years 2023–2025: free cash flow ¥976.2M, net income ¥5.06B.
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 14,095 | 12,276 | 11,538 | 10,266 | 7,444 | 5,134 | 3,757 | 2,908 | 2,294 | 1,634 |
| Cost of revenue | 9,205 | 8,091 | 7,422 | 6,502 | 4,768 | 3,215 | 2,424 | 1,958 | 1,522 | 1,160 |
| Gross profit | 4,890 | 4,184 | 4,116 | 3,764 | 2,676 | 1,919 | 1,333 | 950 | 772 | 474 |
| Selling, general and administrative | 2,123 | 1,886 | 1,895 | 1,749 | 1,033 | 761 | 574 | 461 | 374 | 280 |
| Research and development | 576 | 469 | 448 | 282 | 152 | 105 | 62.9 | 31.6 | 22.6 | — |
| Operating income | 2,045 | 1,719 | 1,690 | 1,667 | 1,448 | 1,020 | 665 | 431 | 360 | 188 |
| EBIT | 2,045 | 1,719 | 1,690 | 1,667 | 1,448 | 1,020 | 665 | 431 | 360 | 188 |
| EBITDA | 3,052 | 2,597 | 2,431 | 2,227 | 1,852 | 1,325 | 928 | 641 | 504 | 281 |
| Interest expense | 193 | 244 | 182 | 167 | 83.1 | 23.9 | 82.5 | 82.4 | 60.3 | 17.5 |
| Pre-tax income | 1,913 | 2,091 | 1,838 | 1,666 | 1,911 | 1,319 | 633 | 393 | 279 | 215 |
| Income tax | 358 | 377 | 256 | 314 | 291 | 172 | 102 | 59.7 | 51.5 | 37.6 |
| Net income | 1,664 | 1,793 | 1,601 | 1,375 | 1,661 | 1,172 | 547 | 333 | 231 | 177 |
| Net income to common shareholders | 1,664 | 1,793 | 1,601 | 1,375 | 1,661 | 1,172 | 547 | 333 | 231 | 177 |
| Basic EPS | 0.94 | 1.01 | 0.90 | 0.78 | 0.93 | 0.66 | 0.37 | 0.25 | 0.17 | 0.16 |
| Diluted EPS | 0.94 | 1.01 | 0.90 | 0.77 | 0.91 | 0.66 | 0.37 | 0.25 | 0.17 | 0.16 |
| Average shares (basic) | 1,762 | 1,770 | 1,772 | 1,774 | 1,781 | 1,779 | 1,486 | 1,329 | 1,332 | 1,137 |
| Average shares (diluted) | 1,771 | 1,773 | 1,775 | 1,776 | 1,820 | 1,785 | 1,487 | 1,329 | 1,332 | 1,137 |
| Dividend per share | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.13 | 0.07 | 0.05 | — | — |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 4,408 | 4,017 | 3,578 | 4,009 | 3,645 | 3,342 | 3,099 | 3,458 | 3,213 | 2,934 | 2,671 | 2,978 |
| Cost of revenue | 2,939 | 2,697 | 2,416 | 2,571 | 2,381 | 2,197 | 2,056 | 2,261 | 2,098 | 1,934 | 1,799 | 1,940 |
| Gross profit | 1,469 | 1,320 | 1,163 | 1,439 | 1,264 | 1,145 | 1,043 | 1,198 | 1,114 | 1,000 | 872 | 1,038 |
| Selling, general and administrative | 589 | 588 | 520 | 554 | 541 | 483 | 466 | 450 | 466 | 473 | 454 | 452 |
| Research and development | 155 | 156 | 140 | 184 | 141 | 128 | 122 | 137 | 124 | 114 | 93.6 | 152 |
| Operating income | 668 | 538 | 462 | 630 | 534 | 500 | 434 | 525 | 510 | 378 | 307 | 336 |
| EBIT | 668 | 538 | 462 | 630 | 534 | 500 | 434 | 525 | 510 | 378 | 307 | 336 |
| EBITDA | 919 | 834 | 713 | 881 | 754 | 744 | 654 | 744 | 695 | 586 | 492 | 521 |
| Interest expense | 51.4 | 48.4 | 51.6 | 51.1 | 47.5 | 50.3 | 43.9 | 116 | 58.4 | 67.7 | 70.6 | 48.1 |
| Pre-tax income | 612 | 513 | 413 | 584 | 516 | 449 | 364 | 469 | 395 | 958 | 269 | 517 |
| Income tax | 114 | 112 | 102 | 94.5 | 103 | 76.2 | 83.9 | 124 | 109 | 91.2 | 52.7 | 69.7 |
| Net income | 497 | 415 | 335 | 523 | 440 | 396 | 306 | 372 | 308 | 883 | 231 | 462 |
| Net income to common shareholders | 497 | 415 | 335 | 523 | 440 | 396 | 306 | 372 | 308 | 883 | 231 | 462 |
| Basic EPS | 0.27 | 0.23 | 0.19 | 0.30 | 0.25 | 0.22 | 0.17 | 0.21 | 0.17 | 0.50 | 0.13 | 0.26 |
| Diluted EPS | 0.27 | 0.23 | 0.19 | 0.29 | 0.25 | 0.22 | 0.17 | 0.21 | 0.17 | 0.50 | 0.13 | 0.26 |
| Average shares (basic) | 1,826 | 1,823 | 1,803 | 1,764 | 1,763 | 1,761 | 1,760 | 1,766 | 1,768 | 1,771 | 1,774 | 1,776 |
| Average shares (diluted) | 1,834 | 1,835 | 1,813 | 1,793 | 1,766 | 1,763 | 1,763 | 1,774 | 1,768 | 1,775 | 1,776 | 1,779 |
| Dividend per share | — | — | — | 0.20 | — | — | — | 0.20 | — | — | — | 0.20 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 27,094 | 23,927 | 26,477 | 20,493 | 18,389 | 11,909 | 9,935 | 4,801 | 3,919 | 2,805 |
| Current assets | 7,778 | 7,608 | 10,874 | 6,536 | 8,644 | 5,540 | 5,944 | 1,275 | 1,078 | 1,097 |
| Cash and equivalents | 1,017 | 1,690 | 5,919 | 1,497 | 3,544 | 2,942 | 4,460 | 321 | 305 | 470 |
| Short-term investments | 886 | 257 | 179 | 613 | 1,080 | — | — | — | — | — |
| Receivables | 3,246 | 2,998 | 2,717 | 2,286 | 1,516 | 1,249 | 992 | 730 | 588 | 452 |
| Inventory | 1,472 | 1,117 | 1,013 | 1,041 | 680 | 282 | 157 | 120 | 93.3 | 92.6 |
| Net property, plant and equipment | 11,970 | 10,798 | 10,062 | 8,464 | 5,811 | 3,799 | 2,882 | 2,555 | 2,094 | 742 |
| Goodwill | 3,586 | 2,761 | 2,781 | 2,688 | 2,096 | 1,166 | 203 | 140 | 134 | — |
| Other intangible assets | 1,197 | 791 | 789 | 803 | 693 | 566 | 421 | 390 | 302 | 21.8 |
| Long-term investments | 1,158 | 883 | 1,005 | 1,008 | 763 | 402 | 190 | 52.9 | 3.3 | 3.5 |
| Current liabilities | 8,364 | 4,224 | 3,654 | 3,912 | 2,982 | 1,982 | 1,270 | 1,308 | 941 | 661 |
| Accounts payable | 607 | 477 | 412 | 406 | 316 | 191 | 118 | 108 | 91.6 | 61.3 |
| Long-term debt | 1,772 | 4,377 | 8,200 | 4,454 | 4,423 | 395 | 542 | 876 | 829 | 315 |
| Total debt | 5,775 | 5,211 | 9,121 | 5,454 | 4,863 | 674 | 826 | 1,258 | 1,089 | 465 |
| Total liabilities | 11,355 | 9,705 | 13,239 | 9,653 | 8,094 | 2,975 | 2,097 | 2,475 | 1,909 | 1,041 |
| Total equity (incl. minority) | 15,739 | 14,223 | 13,238 | 10,840 | 10,295 | 8,934 | 7,838 | 2,326 | 2,010 | 1,763 |
| Retained earnings | 8,568 | 7,257 | 5,818 | 4,574 | 3,554 | 2,131 | 1,078 | 602 | 279 | 48.5 |
| Minority interest | 674 | 604 | 681 | 291 | 166 | 63.4 | 71.0 | 13.0 | 12.6 | — |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 32,241 | 28,946 | 28,562 | 27,094 | 25,801 | 25,197 | 24,333 | 23,927 | 23,570 | 22,997 | 25,244 | 26,477 |
| Current assets | 11,583 | 8,870 | 9,051 | 7,778 | 7,813 | 7,593 | 7,384 | 7,608 | 7,098 | 7,071 | 9,448 | 10,874 |
| Cash and equivalents | 3,132 | 1,576 | 2,379 | 1,017 | 1,205 | 1,302 | 1,263 | 1,690 | 2,001 | 2,401 | 4,633 | 5,919 |
| Short-term investments | 902 | 876 | 598 | 886 | — | 675 | 1,415 | 257 | — | 57.1 | 146 | 179 |
| Receivables | 3,686 | 3,839 | 3,266 | 3,246 | 3,069 | 3,066 | 2,900 | 2,998 | 2,893 | 2,718 | 2,653 | 2,717 |
| Inventory | 2,205 | 1,935 | 1,694 | 1,472 | 1,396 | 1,305 | 1,167 | 1,117 | 1,196 | 1,188 | 1,071 | 1,013 |
| Net property, plant and equipment | 13,051 | 12,536 | 12,194 | 11,970 | 11,574 | 11,324 | 10,964 | 10,798 | 10,538 | 10,173 | 10,170 | 10,062 |
| Goodwill | 3,483 | 3,508 | 3,535 | 3,586 | 2,980 | 2,985 | 2,947 | 2,761 | 2,841 | 2,788 | 2,778 | 2,781 |
| Other intangible assets | 1,242 | 1,258 | 1,168 | 1,197 | 859 | 873 | 838 | 791 | 801 | 786 | 787 | 789 |
| Long-term investments | 1,520 | 1,488 | 1,218 | 1,158 | 1,211 | 1,180 | 1,073 | 883 | 1,092 | 968 | 1,021 | 1,005 |
| Current liabilities | 11,168 | 8,722 | 8,370 | 8,364 | 5,194 | 4,978 | 4,224 | 4,224 | 4,156 | 3,911 | 3,756 | 3,654 |
| Accounts payable | 867 | 761 | 628 | 607 | 565 | 528 | 484 | 477 | 486 | 503 | 385 | 412 |
| Long-term debt | 2,134 | 1,920 | 1,844 | 1,772 | 4,296 | 4,209 | 4,357 | 4,377 | 4,330 | 4,337 | 6,922 | 8,200 |
| Total debt | 6,134 | 5,814 | 5,904 | 5,775 | 5,149 | 5,079 | 5,160 | 5,211 | 5,195 | 5,237 | 7,718 | — |
| Total liabilities | 14,651 | 11,896 | 11,447 | 11,355 | 10,619 | 10,328 | 9,687 | 9,705 | 9,544 | 9,325 | 11,887 | 13,239 |
| Total equity (incl. minority) | 17,590 | 17,051 | 17,115 | 15,739 | 15,182 | 14,869 | 14,646 | 14,223 | 14,026 | 13,672 | 13,357 | 13,238 |
| Retained earnings | 9,450 | 8,953 | 8,904 | 8,568 | 8,045 | 7,606 | 7,563 | 7,257 | 6,885 | 6,577 | 6,048 | 5,818 |
| Minority interest | 700 | 702 | 656 | 674 | 569 | 603 | 604 | 604 | 639 | 659 | 670 | 681 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 3,221 | 2,577 | 2,754 | 2,143 | 2,058 | 1,649 | 939 | 791 | 552 | 236 |
| Depreciation and amortization | 1,163 | 1,049 | 927 | 696 | 498 | 375 | 318 | 262 | 145 | 92.9 |
| Capital expenditure | -2,669 | -2,041 | -2,865 | -2,950 | -2,093 | -1,316 | -755 | -641 | -935 | -1,055 |
| Investing cash flow | -4,374 | -2,024 | -2,251 | -2,209 | -5,258 | -3,371 | -1,045 | -715 | -1,280 | -1,139 |
| Financing cash flow | 377 | -4,797 | 3,915 | -1,417 | 3,661 | -280 | 4,246 | -69.0 | 572 | 1,281 |
| Dividends paid | -531 | -542 | -445 | -405 | -285 | -135 | -143 | -74.6 | -60.6 | -14.4 |
| Share repurchases | -6.7 | -286 | -0.8 | -393 | -284 | — | — | — | — | — |
| Debt issued | 2,866 | 1,322 | 4,171 | 590 | 4,621 | 733 | 727 | 541 | 931 | 521 |
| Debt repaid | -1,947 | -5,295 | -767 | -839 | -300 | -870 | -1,289 | -535 | -299 | -147 |
| Effect of exchange rates | -3.9 | 78.1 | 11.4 | 73.0 | -45.5 | -85.7 | -4.3 | 6.5 | -12.9 | 9.3 |
| Net change in cash | -780 | -4,166 | 4,429 | -1,410 | 416 | -2,088 | 4,135 | 13.6 | -168 | 387 |
| Free cash flow | 552 | 536 | -112 | -807 | -34.8 | — | — | — | — | — |
| Levered free cash flow | -328 | 39.6 | -1,483 | -1,678 | -479 | 27.2 | -159 | -45.3 | -580 | -1,484 |
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 822 | 480 | 604 | 785 | 1,028 | 555 | 853 | 806 | 671 | 354 | 746 | 724 |
| Depreciation and amortization | -666 | 666 | — | 1,163 | -565 | 565 | — | 1,049 | -504 | 504 | — | 927 |
| Capital expenditure | -838 | -789 | -579 | -769 | -746 | -598 | -556 | -542 | -549 | -452 | -499 | -625 |
| Investing cash flow | -1,826 | -1,053 | -243 | -1,631 | -1,006 | -525 | -1,212 | -1,127 | -887 | 456 | -467 | -443 |
| Financing cash flow | 2,174 | -241 | 1,106 | 603 | -125 | -2.1 | -98.9 | -10.7 | -133 | -3,140 | -1,513 | 3,484 |
| Dividends paid | -435 | -55.9 | -47.0 | -46.0 | -398 | -45.9 | -40.7 | -43.1 | -110 | -343 | -46.3 | -49.7 |
| Share repurchases | — | -3.5 | — | -6.7 | — | -6.7 | — | -286 | — | -151 | — | -0.8 |
| Debt issued | 3,411 | 525 | 319 | 1,541 | 875 | 302 | 148 | 528 | 571 | 118 | 104 | 3,679 |
| Debt repaid | -610 | -711 | -302 | -1,060 | -429 | -319 | -139 | -570 | -391 | -2,825 | -1,510 | -299 |
| Effect of exchange rates | -21.9 | -15.9 | -23.0 | -19.5 | 0.4 | 6.4 | 8.8 | 22.8 | -2.3 | 51.2 | 6.5 | 1.3 |
| Net change in cash | 1,148 | -830 | 1,444 | -263 | -102 | 34.5 | -449 | -309 | -351 | -2,279 | -1,228 | 3,766 |
| Free cash flow | -15.6 | -309 | 25.3 | 16.4 | 281 | -43.0 | 297 | 265 | 122 | -97.5 | 247 | 99.4 |
| Levered free cash flow | -85.4 | 455 | -1,184 | 1,309 | -1,830 | 765 | -485 | 872 | -991 | 196 | -81.0 | 663 |
Financial statements of similar companies
Companies in the group: same industry, similar size
